Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Intravitreal RO7200220 vs Lucentis in Diabetic Macular Edema
2021-003756-16Phase 2Active
- Sponsor
- Roche
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vamikibart in diabetic macular edema (DME) (2 arms), sponsored by Roche. Primary endpoint: Primary: Change from baseline in BCVA averaged over Week 20 and Week 24 in treatment-naïve participants. Started Dec 2021; status: active.
02
Drugs
vamikibart
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2021-003756-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003756-16.